SERPINC1 and Sepsis: There are also many alternative compounds to rhAPC that are currently in Phase III clinical trials which include TFPI, TNF-antibody fragment, antithrombin III and platelet-activating factor acetylhydrolase (74), although TFI and antithrombin have been ineffective against severe sepsis and septic shock (75, 76).